In this episode, I talk about DeepMind’s AlphaFold and the company Isomorphic Labs, and why their work in AI-driven drug discovery might be more important than we realize.

While generative AI gets most of the attention for writing text or creating images, AlphaFold operates at a deeper level — predicting the 3D structure of proteins, which are fundamental to how our bodies function. Isomorphic Labs is building on that technology to design drugs that could potentially target specific cancer cells more precisely.

This isn’t as flashy as robots or self-driving cars, but it may have a far greater impact on human health. With partnerships already in place and clinical applications possibly on the horizon, AI-driven drug discovery could quietly reshape medicine over the next decade.

In this episode, I reflect on what it means for AI to move from generating content to helping design treatments — and how that shift could change the future of healthcare.